Samuel O'Brient

Samuel O'Brient

Expertise: Global Financial Markets, Macroeconomics and Geopolitics

Education: BA, Economics & Political Science, Sarah Lawrence College; MSc, International Politics, Trinity College Dublin

Awards & Accomplishments: Published in Curlew Quarterly. Quoted in Forbes. Interviewed by Foreign Policy.

About Samuel
Samuel O’Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy. O’Brient writes a weekly column on recent political news that investors should be following.

From his early days at InvestorPlace, O’Brient found himself drawn to the booming world of electric vehicles and green energy. His coverage of mining and other battery components has made him an expert source for industry publications. During his early years as an Economic Policy Analyst at U.S. Resist News, he gained expertise in international trade as the U.S.-China trade war dominated headlines. This in-depth research and analysis experience helped strengthen his prowess in all things political economy. O’Brient brings this expertise to work with him every day, thoughtfully analyzing how the daily happenings on the Capitol trickle down to Wall Street… and how retail investors can take action to profit.

An experienced journalist, editor, and economic policy analyst, O’Brient has spent his career guided by a deep passion for economic theory and policy. As a financial blogger on TipRanks, he has received 4.6 stars and is ranked in the top 10% of stock pickers.

O’Brient’s work on economic and tech policy has been curated by popular outlets Marker, OneZero and Gen.

He can be reached on LinkedIn and Muck Rack.

Recent Articles

SBUX Stock Brews Tension Ahead of Dec. 8 Starbucks Union Vote. What to Know.

Buffalo, NY, Starbucks baristas are about to vote on whether or not they should unionize. Here's what it may mean for SBUX stock.

Floki Inu Price Predictions: How High Can the Metaverse Take the FLOKI Crypto?

Expansions into the metaverse and DeFi spaces have experts issuing positive Floki Inu price predictions for the year ahead.

Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today

Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.

Dear NVAX Stock Fans, Mark Your Calendars for a Key Catalyst on Dec. 16

Novavax may be on the verge of receiving EUA from the WHO, but NVAX stock isn't moving much so far. Regardless, investors should be on watch.

DWAC Stock Stumbles on SEC Probe. Here’s 7 Things to Know.

DWAC stock is falling amid discussion of a probe from both the SEC and FINRA. Here's what investors should keep in mind as we learn more.